Linlin Yang

List of Publications by Citations

Source: https://exaly.com/author-pdf/288139/linlin-yang-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12 papers	1,327 citations	8 h-index	15 g-index
15 ext. papers	1,797 ext. citations	14.2 avg, IF	4.33 L-index

#	Paper	IF	Citations
12	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*, **2020**, 369, 956-963	33.3	906
11	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science*, **2021**, 371, 823-829	33.3	157
10	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nature Communications*, **2021**, 12, 2938	17.4	110
9	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection **2020**,		40
8	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model **2020**,		35
7	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. *PLoS Pathogens*, **2020**, 16, e1009089	7.6	33
6	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. *Nature Communications*, **2021**, 12, 3309	17.4	25
5	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 **2020**,		11
4	Drainage of inflammatory macromolecules from the brain to periphery targets the liver for macrophage infiltration. *ELife*, **2020**, 9,	8.9	6
3	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody **2020**,		2
2	Liposomal Clodronate-mediated Macrophage Depletion in the Zebrafish Model. *Bio-protocol*, **2021**, 11, e3951	0.9	1
1	A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum.. *PLoS Pathogens*, **2022**, 18, e1010409	7.6	0